-
Prednisolone (B2012) for Reliable Cell Assays
2026-09-30
This scenario-based guide explains how Prednisolone (SKU B2012), a high-purity synthetic glucocorticoid, can support better-controlled viability, proliferation, and cytotoxicity experiments. It covers receptor biology, solvent compatibility, stock preparation, data interpretation, and practical supplier selection without confusing glucocorticoid signaling with ERAD-based protein degradation.
-
Cy3 NHS ester (non-sulfonated) Workflow Guide
2026-09-30
This guide explains how Cy3 NHS ester (non-sulfonated), SKU A8100, can be used for covalent fluorescent labeling of amino-containing proteins, peptides, and oligonucleotides. It is appropriate when DMSO, DMF, or another organic co-solvent is acceptable, but it is not the preferred choice for fully aqueous workflows or delicate proteins that cannot tolerate organic solvent.
-
Phenothiazines, ROS, and Autophagy in Macrophages
2026-09-29
A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage antibacterial activity by increasing reactive oxygen species, lysosomal function, and autophagy. Perphenazine also reduced tissue lesions and inflammation in a Salmonella Typhimurium infection model, supporting phenothiazines as host-directed lead compounds while leaving receptor specificity, dosing, and clinical translation unresolved.
-
Rotigotine Nose-to-Brain Delivery in PD Models
2026-09-29
Bhattamisra and colleagues developed rotigotine-loaded chitosan nanoparticles for intranasal nose-to-brain delivery and evaluated them in SH-SY5Y cells and a haloperidol-induced rat model. The formulation showed cellular compatibility, altered neurotoxicity-related biomarkers, improved motor outcomes, and increased brain-targeting efficiency, while the study also highlights important limits of acute models for Parkinson’s disease translation.
-
Z-YVAD-FMK Workflows for Caspase-1 Assays
2026-09-28
Use Z-YVAD-FMK to test whether caspase-1 contributes to inflammatory signaling and cell death—not as a stand-in for a general apoptosis inhibitor. This workflow pairs a practical dose-finding plan with controls that help distinguish caspase-1-dependent responses from bystander necroptosis.
-
SCH772984 HCl: ERK1/2 Inhibitor Workflows
2026-09-27
Use SCH772984 HCl to test whether ERK1/2 activity sustains MAPK output, tumor-cell growth, or TERT expression. This practical guide connects cancer-model workflows with a recent human stem-cell study while keeping its findings distinct from proposed experiments.
-
HyperScript™ Reverse Transcriptase in Fusion-RNA Assays
2026-09-26
HyperScript™ Reverse Transcriptase can support RNA-to-cDNA conversion when fusion transcripts are structured or scarce. This article connects enzyme choice to assay design and interpretation in FGFR2 fusion research, while distinguishing measurement quality from therapeutic evidence.
-
Phosphatase Inhibitor Cocktail 3 for YAP Studies
2026-09-26
Preserve phosphorylation during lysis when investigating Hippo–YAP signaling, RNF166, and angiomotins. This practical guide shows how Phosphatase Inhibitor Cocktail 3 can support phosphoprotein analysis while keeping phosphatase inhibition distinct from the PARylation mechanism at the center of the colorectal cancer study.
-
Hoechst 33342/PI Double Staining Kit: Practical Guide
2026-09-25
The Hoechst 33342/PI Double Staining Kit provides a fluorescence-based way to assess nuclear chromatin appearance alongside cell membrane integrity, helping researchers distinguish staining patterns associated with viable, apoptotic, and membrane-compromised cells. It is for laboratory research, not diagnosis or medical use; stain volumes, incubation conditions, and instrument settings should be established from the current kit instructions and validated for the sample type.
-
Phenothiazines Boost Macrophage Antibacterial Activity
2026-09-25
Qiu and colleagues report that phenothiazines strengthen macrophage antibacterial activity alongside increased reactive oxygen species, autophagy, and lysosomal activity. In a mouse infection model, perphenazine reduced Salmonella-associated tissue lesions and inflammation, supporting further study of host-directed strategies while leaving dose, mechanism, and clinical relevance to be established.
-
H-151 Links STING Inhibition to Ferroptosis Control
2026-09-24
The study identifies H-151 as more than a STING inhibitor: it also traps radicals and suppresses ferroptosis through a STING-independent mechanism. In a murine renal ischemia-reperfusion model, this combination of anti-inflammatory and antioxidant activity reduced tissue injury and improved renal function, supporting further investigation of dual-pathway intervention.
-
PPARγ Activation Shifts Macrophages in DSS Colitis
2026-09-24
In a cell and mouse model of inflammatory bowel disease, PPARγ activation was associated with a shift toward M2 macrophage markers, altered STAT-1/STAT-6 phosphorylation, and less severe DSS-induced colitis. The findings connect macrophage polarization with intestinal barrier outcomes, while leaving questions about pathway causality, treatment timing, and relevance to human disease for future work.
-
Rotigotine Hydrochloride: An Assay Design Guide
2026-09-23
Rotigotine hydrochloride is more than a dopamine D2/D3 receptor agonist: its receptor breadth and exposure-dependent biology demand careful assay design. This guide connects continuous dopaminergic delivery, disease-model selection, formulation, and translational interpretation for rigorous Parkinson’s disease research.
-
PD 0332991: A Mechanism-First Assay Guide
2026-09-22
PD 0332991 and Palbociclib HCl provide a precise way to interrogate CDK4/6-dependent cell-cycle control. This mechanism-first guide connects Rb biology with IL-6/GP130 pathway research while emphasizing assay selection, interpretation, and translational limits.
-
Rotigotine Hydrochloride: From Receptor Map to Assay
2026-09-22
Rotigotine hydrochloride is more than a dopamine D2/D3 receptor agonist: it is a tool for dissecting exposure, receptor signaling, and neurobehavioral outcomes. This guide translates pharmacology and transdermal-delivery evidence into practical assay decisions for Parkinson’s disease research.